ILLUMINA (#ILMN) Weekly Special Report based on 1.00 Lot Calculation:
ILLUMINA:
- Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. The company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers and through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
- PRODUCTS: products help pioneer advances in oncology, genetic and infectious diseases, reproductive health, and beyond.
NEWS AND EVENTS
- Illumina launches latest chemistry across most popular mid-throughput sequencers: Illumina Inc. a global leader in DNA sequencing and array-based technologies, announced that it has completed integration of its latest chemistry, XLEAP-SBS™, into all reagents for its NextSeq™ 1000 and NextSeq 2000 next-generation sequencing (NGS) instruments. "We are excited to deliver for our NextSeq 1000/2000 customers improved sequencing with faster run times, better quality, and higher output—all at lower cost per kit," said Jason Johnson, head of Global Product Management at Illumina. "XLEAP-SBS chemistry on NextSeq 1000/2000 will enable labs to perform bigger NGS projects without raising the budget, and facilitate greater adoption of multiomic approaches."
- Illumina DRAGEN v4.3 powers most comprehensive, accurate genome with industry-leading innovations (June 11,): Illumina Inc. announced the launch of DRAGEN™ v4.3, the latest version of its DRAGEN™ software, part of the Illumina Connected Software portfolio, for analysis of next-generation sequencing data. DRAGEN's innovation in multigenome mapping complements the efforts led by the Human Pangenome Reference Consortium (HPRC). The HPRC, funded by the National Human Genome Research Institute, aims to equip the genomics community with high-quality assemblies from diverse ancestries and combine them into a reference human pangenome.
PRICE ACTION
- STOCK PRICE ACTION: THE STOCK HAS TRADED AROUND 81% BELOW ITS ALL- TIME HIGH OF $554.32 (February 2021): Illumina was last trading around $104, and if a full recovery follows to recent all- time highs, the stock could see an upside of around 430%. However, the price could decline.
- ANALYST OPINION: Citigroup target $136.95; JPMorgan targets $126.34; HSBC targets $126.34; Bloomberg Consensus targets $136.58.
#ILLUMINA July 1, 2024
Current Price: 104.00
|
Illumina |
Weekly |
|
Trend direction |
|
|
140.00 |
|
|
129.00 |
|
|
117.00 |
|
|
93.00 |
|
|
90.00 |
|
|
87.00 |
Example of calculation base on weekly trend direction for 1.00 Lot1
|
|
||||||
|
Profit or loss in $ |
36,000.00 |
25,000.00 |
13,000.00 |
-11,000.00 |
-14,000.00 |
-17,000.00 |
|
Profit or loss in €² |
33,481.83 |
23,251.27 |
12,090.66 |
-10,230.56 |
-13,020.71 |
-15,810.86 |
|
Profit or loss in £² |
28,416.60 |
19,733.75 |
10,261.55 |
-8,682.85 |
-11,050.90 |
-13,418.95 |
|
Profit or loss in C$² |
49,271.22 |
34,216.13 |
17,792.39 |
-15,055.10 |
-19,161.03 |
-23,266.97 |
1. 1.00 lot is equivalent of 1000 units
2. Calculations for exchange rate used as of 11:00 (GMT+1) 01/07/2024
Fortrade recommends the use of Stop-Loss and Take-Profit, please speak to your Senior Account ManagerClient Manager regarding their use.
- You may wish to consider closing your position in profit, even if it is lower than suggested one
- Trailing stop technique can protect the profit – Ask your Senior Account ManagerClient Manager for more details